ROQ vs. APTA, CIZ, HEMO, EVG, MTFB, DEST, GENF, VAL, BSFA, and RENE
Should you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include Aptamer Group (APTA), Cizzle Biotechnology (CIZ), Hemogenyx Pharmaceuticals (HEMO), Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Genflow Biosciences (GENF), ValiRx (VAL), BSF Enterprise (BSFA), and ReNeuron Group (RENE). These companies are all part of the "biotechnology" industry.
Roquefort Therapeutics vs. Its Competitors
Roquefort Therapeutics (LON:ROQ) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.
Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500.
Aptamer Group has a net margin of -343.95% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -29.57% beat Aptamer Group's return on equity.
1.7% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Aptamer Group shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by insiders. Comparatively, 13.2% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.
Roquefort Therapeutics has higher earnings, but lower revenue than Aptamer Group. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.
Summary
Roquefort Therapeutics beats Aptamer Group on 6 of the 11 factors compared between the two stocks.
Get Roquefort Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ROQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roquefort Therapeutics Competitors List
Related Companies and Tools
This page (LON:ROQ) was last updated on 8/10/2025 by MarketBeat.com Staff
